Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastrophe

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• MYC overexpression is a known driver of cancer, but direct therapeutic targeting remains difficult.
• Developing effective cancer therapies that selectively target cancer cells is a significant challenge.

Purpose of the Study:

• To identify and characterize novel therapeutic agents targeting MYC-driven cancers.
• To investigate the mechanism of action and efficacy of DL78 as a selective anticancer agent.

Main Methods:

• Screening for antimitotic agents with selective anticancer activity.
• Evaluating DL78 efficacy in vitro across nine cancer types and in vivo using a platinum-resistant ovarian cancer model.
• Investigating the molecular mechanism of DL78 action, focusing on MYC interactions and cell cycle regulation.

Main Results:

• DL78 demonstrated broad anticancer efficacy, inhibiting growth in nine cancer types and reducing tumor burden in ovarian cancer models with no observed toxicity.
• DL78 preferentially targets chromosomally unstable, MYC-overexpressing cancer cells.
• DL78 disrupts the interaction between MYC and α-tubulin, inducing mitotic arrest, mitotic catastrophe, and apoptosis in cancer cells while sparing normal cells.

Conclusions:

• DL78 is a potent antimitotic agent with selective anticancer activity mediated by MYC regulation.
• DL78 represents a novel therapeutic strategy for MYC-driven cancers by inducing mitotic catastrophe through disruption of MYC-α-tubulin interaction.
• This approach offers a new paradigm for MYC-targeted cancer therapy, distinct from targeting MYC's transcriptional activity.